Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark N Prichard

Showing results (71-80 of 80) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 80 results.
Plos One|February 25, 2010
Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitroJack T Nguyen, Justin D Hoopes, Minh H Le, et al.
Journal of Virology|March 7, 2008
Human cytomegalovirus UL97 kinase activity is required for the hyperphosphorylation of retinoblastoma protein and inhibits the formation of nuclear aggresomesMark N Prichard, Elizabeth Sztul, Shannon L Daily, et al.
Antimicrobial Agents and Chemotherapy|September 23, 2009
Inhibition of herpesvirus replication by 5-substituted 4'-thiopyrimidine nucleosidesMark N Prichard, Debra C Quenelle, Caroll B Hartline, et al.
Journal of Medicinal Chemistry|December 10, 2016
Synthesis and Antiviral Evaluation of Octadecyloxyethyl Benzyl 9-[(2-Phosphonomethoxy)ethyl]guanine (ODE-Bn-PMEG), a Potent Inhibitor of Transient HPV DNA AmplificationJames R Beadle, Nadejda Valiaeva, Guang Yang, et al.
Antiviral Research|March 7, 2018
USC-087 protects Syrian hamsters against lethal challenge with human species C adenovirusesKaroly Toth, Jacqueline F Spencer, Baoling Ying, et al.
Journal of Virology|November 8, 2013
New small molecule entry inhibitors targeting hemagglutinin-mediated influenza a virus fusionArnab Basu, Aleksandar Antanasijevic, Minxiu Wang, et al.
Antiviral Research|December 13, 2022
Investigating N-arylpyrimidinamine (NAPA) compounds as early-stage inhibitors against human cytomegalovirusAndrea J Parsons, Sabrina I Ophir, Thomas J Gardner, et al.
The Journal of Infectious Diseases|December 12, 2012
Oseltamivir pharmacokinetics, dosing, and resistance among children aged <2 years with influenzaDavid W Kimberlin, Edward P Acosta, Mark N Prichard, et al.
Molecular Pharmaceutics|December 9, 2022
NPP-669, a Novel Broad-Spectrum Antiviral Therapeutic with Excellent Cellular Uptake, Antiviral Potency, Oral Bioavailability, Preclinical Efficacy, and a Promising Safety MarginElke Lipka, Aaron M Chadderdon, Cheryl C Harteg, et al.
The New England Journal of Medicine|March 5, 2015
Valganciclovir for symptomatic congenital cytomegalovirus diseaseDavid W Kimberlin, Penelope M Jester, Pablo J Sánchez, et al.
Pageof 8

Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
Plos One|February 25, 2010
Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitroJack T Nguyen, Justin D Hoopes, Minh H Le, et al.
Journal of Virology|March 7, 2008
Human cytomegalovirus UL97 kinase activity is required for the hyperphosphorylation of retinoblastoma protein and inhibits the formation of nuclear aggresomesMark N Prichard, Elizabeth Sztul, Shannon L Daily, et al.
Antimicrobial Agents and Chemotherapy|September 23, 2009
Inhibition of herpesvirus replication by 5-substituted 4'-thiopyrimidine nucleosidesMark N Prichard, Debra C Quenelle, Caroll B Hartline, et al.
Journal of Medicinal Chemistry|December 10, 2016
Synthesis and Antiviral Evaluation of Octadecyloxyethyl Benzyl 9-[(2-Phosphonomethoxy)ethyl]guanine (ODE-Bn-PMEG), a Potent Inhibitor of Transient HPV DNA AmplificationJames R Beadle, Nadejda Valiaeva, Guang Yang, et al.
Antiviral Research|March 7, 2018
USC-087 protects Syrian hamsters against lethal challenge with human species C adenovirusesKaroly Toth, Jacqueline F Spencer, Baoling Ying, et al.
Journal of Virology|November 8, 2013
New small molecule entry inhibitors targeting hemagglutinin-mediated influenza a virus fusionArnab Basu, Aleksandar Antanasijevic, Minxiu Wang, et al.
Antiviral Research|December 13, 2022
Investigating N-arylpyrimidinamine (NAPA) compounds as early-stage inhibitors against human cytomegalovirusAndrea J Parsons, Sabrina I Ophir, Thomas J Gardner, et al.
The Journal of Infectious Diseases|December 12, 2012
Oseltamivir pharmacokinetics, dosing, and resistance among children aged <2 years with influenzaDavid W Kimberlin, Edward P Acosta, Mark N Prichard, et al.
Molecular Pharmaceutics|December 9, 2022
NPP-669, a Novel Broad-Spectrum Antiviral Therapeutic with Excellent Cellular Uptake, Antiviral Potency, Oral Bioavailability, Preclinical Efficacy, and a Promising Safety MarginElke Lipka, Aaron M Chadderdon, Cheryl C Harteg, et al.
The New England Journal of Medicine|March 5, 2015
Valganciclovir for symptomatic congenital cytomegalovirus diseaseDavid W Kimberlin, Penelope M Jester, Pablo J Sánchez, et al.
Pageof 8